Composition of active agents to positively affect a robust mammalian endocannabinoid system tone to better address age related discomfort
Compositions and methods for prophylactically sustaining and/or maintaining a robust endocannabinoid system in patients for modulating excess inflammatory response and inflammatory diseases over the mammalian lifespan to mitigate age-related discomfort. Specifically, a method of treating inflammatory and neuropathic pain in a mammal by administering a synergistic pharmaceutical daily dosage form comprising: palmitoylethanolamide (PEA), beta-caryophyllene (BCP) and docosahexaenoic acid (DHA).
1. A method of treating inflammatory and neuropathic pain in a mammal comprising:
administering to a mammal in need thereof a synergistic pharmaceutical daily dosage form comprising: between about 1 and about 2% by weight of palmitoylethanolamide (PEA) in an ultramicronized form, between about 10 and about 30% by weight of beta-caryophyllene (BCP) and between about 10 and about 30% by weight of docosahexaenoic acid (DHA) in liquid form;
wherein a daily dose of the palmitoylethanolamide (PEA) does not exceed about 1200 mg/day, a daily dose of the beta-caryophyllene (BCP) does not exceed about 0.1 mL/kg per kg body weight of the mammal, and a daily dose of the docosahexaenoic acid (DHA) does not exceed about 10 mg/kg per kg body weight of the mammal.
2. The method of claim 1 , wherein the pharmaceutical daily dosage form is an oral or topical dosage form.
3. The method of claim 1 , wherein the pharmaceutical daily dosage form further comprises one or more compounds with anti-inflammatory activity in a total weight percentage ranging between 0 and about 20%.
4. The method of claim 3 , wherein the one or more compounds with anti-inflammatory activity is selected from the group consisting of plant derived terpenes/terpenoids, polyphenols, B vitamins, and combinations thereof.
5. The method of claim 4 , wherein the one or more compounds with anti-inflammatory activity, comprises a terpene comprising one or more of beta-carophyllene and humalene.
6. The method of claim 3 , wherein the one or more compounds with anti-inflammatory activity is one or more polyphenols.
7. The method of claim 6 , wherein the one or more compounds with anti-inflammatory activity comprises a polyphenol selected from the group consisting of Flavonoids, Polyphenolic amides, curcumin, and combinations thereof.
8. The method of claim 7 , wherein the one or more compounds with anti-inflammatory activity are quercetin, a capsaicinoid, and curcumin.
9. The method of claim 3 , wherein the synergistic pharmaceutical daily dosage form is in the form of a tablet, a capsule, or liquid.
10. The method of claim 3 , wherein the one or more compounds with the anti-inflammatory activity is comicronized with the palmitoylethanolamide.
11. The method of claim 1 , wherein the neuropathic pain results from a disease selected from the group consisting of both acute and chronic painful central and peripheral neuropathies; migraines; fibromyalgia; pain associated with vertebral column and spinal cord diseases of traumatic, dysmetabolic and degenerative origin; acute and/or chronic pain associated with diseases in the pelvic area; Irritable Bowel Syndrome; pain associated with traumatic and degenerative joint diseases; pain associated with arthritic diseases, and any combination thereof.
12. The method of claim 1 , wherein the palmitoylethanolamide is in ultra-micronized form (um PEA) with a particle size ranging between about 0.8 and about 6 microns.
13. A method of treating neuropathic and inflammatory pain in a mammal, comprising: administering to a mammal in need thereof a dosage form selected from the group consisting of a chew, tablet, capsule, or a liquid form of a synergistic pharmaceutical composition, wherein each dosage form of the pharmaceutical composition comprises: palmitoylethanolamide (PEA) in a weight percentage between about 1 and about 2%, beta-caryophyllene (BCP) in a weight percentage between about 10 and about 30% and docosahexaenoic acid (DHA) in a weight percentage between about 10 and about 30% and one or more compounds with anti-inflammatory activity in a total weight percentage ranging between 0 and about 20%.
14. The method of claim 13 , wherein said palmitoylethanolamide is in non-micronized form with a particle size ranging between about 50 and about 100 μm, in micronized form (mPEA) with a particle size ranging between about 2 and about 10 μm, or in ultra-micronized form (umPEA) with a particle size ranging between about 0.8 and about 6 μm, or in a mixture of such forms.
15. The method of claim 13 , wherein said beta-caryophyllene (BCP) and docosahexaenoic acid is in a miscible form.
16. The method of claim 2 , wherein the pharmaceutical daily dosage form is topical dosage form.
17. The method of claim 16 , wherein the topical dosage form is selected from the group consisting of a transdermal patch, a cream, a lotion, an ointment, and a powder.
18. The method of claim 1 , wherein the pharmaceutical daily dosage form further comprises one or more of cannabigerol (CBG), cannabidiol (CBD) and cannabidiolic acid (CBDA).